LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiated Phase 2b trial data published in The New England Journal of Medicine Cash position at 30 September 2022 of $173.1 million Conference call today at 8:00am ET (12:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”)…


Previous articlePsychedelic Research Bulletin: October 2022
Next articlePsychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM